WHY IRX-2?

IRX-2: A NOVEL IMMUNOMODULATOR

IRX-2 is a primary, cell-derived biologic with specified levels of active cytokine components that act on various parts of the immune system, thus addressing the need for multiple mechanisms of action in the treatment of head and neck squamous cell carcinomas (especially oral cavity cancers).

IRX-2 COMPONENTS AND TARGETS1-3

THE IRX-2 REGIMENS

IRX-2 is given as part of the IRX-2 regimens, both of which contain additional pharmacologic agents that support IRX-2 in the promotion of an anticancer immune response.

ADDITIONAL PHARMACOLOGIC COMPONENTS IN IRX-24,5

IRX-2 PRODUCTION

IRX-2 is produced under pharmaceutical manufacturing standards from donor mononuclear cells stimulated with phytohemagglutinin (PHA) and other agents that mimic a challenge to the immune system, such as might occur when presented with an infectious pathogen.

© 2016 IRX Therapeutics